The Wright Center for Graduate Medical Education Scranton, PA
Naeem Ijaz, MD1, Umar Hayat, MD2, Saba Afroz, MD3, Muhammad Kamal, MD4, Muhammad Haseeb, MD5, Manesh Kumar Gangwani, MD6, Adil Memon, MD7, Umer Farooq, MD8, Madeeha Sadiq, MD9, Raj Shah, MD10, Yakub Khan, MD3, Faisal Kamal, MD11 1The Wright Center for Graduate Medical Education, Scranton, PA; 2Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA; 3Geisinger Wyoming Valley Hospital, Wilkes-Barre, PA; 4Essen Health Care System, New York, NY; 5Brigham and Women's Hospital, Boston, MA; 6University of Toledo, Toledo, OH; 7Louisiana State University, Shreveport, LA; 8University of Rochester, Rochester, NY; 9East Tennessee State University, Johnson City, TN; 10University of Central Florida HCA Healthcare GME, Kissimmee, FL; 11Thomas Jefferson Health, Philadephia, PA
Introduction: Prior studies have shown that patients with cirrhosis incur a high risk of developing severe disease from COVID-19. However, nationwide data must still be included to assess the impact on severity and outcomes. Therefore, our study aimed to evaluate the impact of cirrhosis on the severity of COVID-19 in hospitalized patients in the US.
Methods: National Inpatient Sample (NIS) for 2020 was queried using ICD-10-CM Codes to identify a cohort of inpatient admissions with a primary discharge diagnosis of COVID-19 and a secondary diagnosis of cirrhosis. A weighted sample was used to get baseline characteristics and resource utilization during the inpatient admissions. Multivariate logistic regression analysis followed by predictive margins was used to obtain adjusted estimates of the intubation and Intensive Care Unit (ICU) care and mortality.
Results: Among 728,230 patients hospitalized with cirrhosis, 11520 (1.5%) patients had a concurrent diagnosis of COVID-19. Compared to males, there was less proportion of females with cirrhosis contracted COVID-19. (58.7% vs. 41.3%). The mean age was similar in cirrhosis patients with and without COVID-19 (63.8 years vs. 60.1 years). The patients admitted with cirrhosis alone had more private insurance than those with Cirrhosis & COVID-19 (19% vs. 17%). Patients with Cirrhosis & COVID-19 had higher adjusted Odds (aOR) of Intubation aOR 2.14 (95% CI 1.91 – 2.41), ICU stays aOR:1.90 (95% CI 1.69 - 2.13) and mortality aOR 3.30 (95% CI 2.95 – 3.69). Cirrhosis patients with COVID-19 had more extended hospitalization and higher hospital charges, which were statistically significant.
Discussion: Our study shows that patients with Cirrhosis+COVID-19 develop more severe disease, given the increased risk of intubation, ICU stays, and mortality. It underscores the importance of early recognition of high-risk individuals during the COVID-19 pandemic and optimizing their health status for better health outcomes.
Figure: COVID-19 outcomes graphs.
Disclosures:
Naeem Ijaz indicated no relevant financial relationships.
Umar Hayat indicated no relevant financial relationships.
Saba Afroz indicated no relevant financial relationships.
Muhammad Kamal indicated no relevant financial relationships.
Muhammad Haseeb indicated no relevant financial relationships.
Manesh Kumar Gangwani indicated no relevant financial relationships.
Adil Memon indicated no relevant financial relationships.
Umer Farooq indicated no relevant financial relationships.
Madeeha Sadiq indicated no relevant financial relationships.
Raj Shah indicated no relevant financial relationships.
Yakub Khan indicated no relevant financial relationships.
Faisal Kamal indicated no relevant financial relationships.
Naeem Ijaz, MD1, Umar Hayat, MD2, Saba Afroz, MD3, Muhammad Kamal, MD4, Muhammad Haseeb, MD5, Manesh Kumar Gangwani, MD6, Adil Memon, MD7, Umer Farooq, MD8, Madeeha Sadiq, MD9, Raj Shah, MD10, Yakub Khan, MD3, Faisal Kamal, MD11. P3777 - Impact of Cirrhosis on Severity of COVID-19 Outcomes in Hospitalized Cohort in the US: A Nationwide Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.
